Blog Cost-Effectiveness of Population Screening for CDC Tier 1 ConditionsBy MBA Katrina Kelly, Head of Market Access and Reimbursement, Helix
Press ReleasesNebraska Medicine & Helix Partner to Provide Precision Care in Nebraska to Help Find Health Issues Individually and StatewideAugust 15, 2023
Press ReleasesSt. Luke’s University Health Network and Helix Partner on Population Genomics Research Program to Accelerate Precision MedicineJune 27, 2023
Press ReleasesHelix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary DiseasesJanuary 5, 2023
1Published ResearchGenomewide Association Study of Severe Covid-19 with Respiratory FailureJune 17, 2023
2Published ResearchCombining rare and common genetic variants improves population risk stratification for breast cancerMay 19, 2023
3Published ResearchEvidence for SARS-CoV-2 Delta and Omicron co-infections and recombinationOctober 19, 2022
4Published ResearchDecoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced MyocarditisOctober 8, 2022
5Published ResearchA Power-based Sliding Window Approach to Evaluate the Clinical Impact of Rare Genetic VariantsJuly 31, 2022